Pharmaceutical

Merck concludes SpringWorks acquisition for $3.4bn

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).

Jul 3, 2025 - 06:00
Merck concludes SpringWorks acquisition for $3.4bn
Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).
Read the original article

Tags:

Previous Article

Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold

Next Article

Cell and gene therapy: The vital role of logistics

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

New York’s new doula plan will cover services for anyone on Medicaid

New York’s new doula plan will cover services for anyon...

Jan 12, 2024

Sandoz concludes acquisition of Mycamine antifungal agent from Astellas

Sandoz concludes acquisition of Mycamine antifungal age...

Aug 28, 2023

Risk adjusted net present value: What is the current va...

Jul 2, 2024